CSBA letter to USITC Expressing Concerns with Proposed WTO TRIPS Waiver Expansion

BIO and its members appreciate the opportunity to work with FDA to develop and align on approaches that are robust, practical, and expedite patient focused drug development. To further enhance the Guidance, we believe that a few areas would benefit…